Thallion Pharmaceuticals Inc.
TSX : TLN

Thallion Pharmaceuticals Inc.

December 10, 2007 16:15 ET

Thallion Announces Changes to Board of Directors

MONTREAL, QUEBEC--(Marketwire - Dec. 10, 2007) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced changes to its Board of Directors. Michael Kurman, M.D., an independent consultant to the pharmaceutical, biotechnology and health care industries, will be joining the Company as a new Board member, bringing 25 years of experience in oncology and anticancer drug development to Thallion. Dr. Sylvie Gregoire has resigned from Thallion's Board of Directors in order to better fulfill her recently assumed professional commitments.

Formerly Vice-President of Clinical Operations for Quintiles' Oncology Division, Dr. Kurman serves on the Scientific Advisory Board of several public and private companies and is on the Board of Directors of Avalon Pharmaceuticals (NASDAQ:AVRX).

"Michael brings substantial experience and knowledge in oncology to Thallion's Board of Directors. As a former investigator on several oncology clinical trials and having been involved in the successful development or launch of four oncology products, his experience will be a key element to the Company's continued growth. Michael's expertise in clinical trial design, regulatory issues and product portfolio management are important to help us reach our goal of becoming a successful oncology product development company," said Lloyd M. Segal, Chief Executive Officer of Thallion. "I would also like to take this opportunity to thank Sylvie for her tremendous contribution over the past years. Her guidance and valuable experience and her extensive knowledge of manufacturing and regulatory affairs were invaluable to us."

Dr. Gregoire has recently been appointed President of Shire's Human Genetic Therapies business. As part of her new responsibilities, she will be managing the commercial and pipeline growth, directing the R&D and portfolio management processes as well as contributing to the execution of the overall strategic direction of Shire's HGT business.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX:TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. Thallion has three active clinical programs at a Phase II, or later, stage of development which include: Shigamabs®, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections; ECO-4601, a novel anti-cancer therapy derived from a nonpathogenic microorganism; and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. Additional information about the Company can be obtained at www.thallion.com.

Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Contact Information